Please ensure Javascript is enabled for purposes of website accessibility

Regeneron's Arthritis Drug Fails COVID-19 Trial

By Cory Renauer – Jul 3, 2020 at 5:01AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Kevzara failed to help the most severely affected COVID-19 patients.

A clinical trial with thousands of hospitalized coronavirus patients failed to hit the mark for the last time on Thursday. A group of COVID-19 patients requiring mechanical ventilation failed to show measurable improvement when treated in a phase 3 trial with Kevzara from Regeneron (REGN 1.50%). In June, Regeneron reported Kevzara's failure to provide a benefit for hospitalized COVID-19 patients severe enough to require oxygen, but not severe enough to require mechanical ventilation.

Worth a shot 

In patients with severe COVID-19 infections, it isn't unusual to see overexcited immune systems do more harm than good. Earlier this year, investigators in China noticed lots of unhelpful immune processes in the lungs initiated by a protein called interleukin-6 (IL-6), and Kevzara seemed like a good fit to address this.

Person in lab writing on clipboard

Image source: Getty Images.

Kevzara is a drug Regeneron markets in partnership with Sanofi (SNY 2.55%) that helps rheumatoid arthritis patients by preventing a protein called interleukin-6 (IL-6) from attacking healthy joints. The trial results showed a minor positive trend that suggested a benefit for patients who required mechanical ventilation when they began treatment, but the trend wasn't strong enough to be considered statistically significant.

In June, investigators from Britain's National Health Service (NHS) reported positive results from a study with over 11,500 enrolled patients who were treated with a decades-old steroid that costs pennies per tablet, dexamethasone. Treatment with the generic steroid reduced patients' risk of death by 35% compared to standard care without dexamethasone.

Regeneron's rheumatoid arthritis gamble flopped, but REGN-COV2, a combination of antibodies that attach to SARS-CoV-2, the virus that causes COVID-19, still has a chance. Investigators began treating COVID-19 patients with Regeneron's REGN-COV2 last month, making it the first antibody-based candidate that uses a pair of proteins to stop SARS-CoV-2 from entering host cells to reach this stage.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
REGN
$705.42 (1.50%) $10.41
Sanofi Stock Quote
Sanofi
SNY
$38.17 (2.55%) $0.95

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
327%
 
S&P 500 Returns
105%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.